PL1838350T3 - Modulatory aktywności ubikwitynazy itch - Google Patents

Modulatory aktywności ubikwitynazy itch

Info

Publication number
PL1838350T3
PL1838350T3 PL06703354T PL06703354T PL1838350T3 PL 1838350 T3 PL1838350 T3 PL 1838350T3 PL 06703354 T PL06703354 T PL 06703354T PL 06703354 T PL06703354 T PL 06703354T PL 1838350 T3 PL1838350 T3 PL 1838350T3
Authority
PL
Poland
Prior art keywords
itch
modulators
ubiquitinase activity
ubiquitinase
activity
Prior art date
Application number
PL06703354T
Other languages
English (en)
Inventor
Gennaro Melino
Mario Rossi
Paolo Salomoni
Original Assignee
Ryboquin Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0501202A external-priority patent/GB0501202D0/en
Application filed by Ryboquin Company Ltd filed Critical Ryboquin Company Ltd
Publication of PL1838350T3 publication Critical patent/PL1838350T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06703354T 2005-01-20 2006-01-19 Modulatory aktywności ubikwitynazy itch PL1838350T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0501202A GB0501202D0 (en) 2005-01-20 2005-01-20 Targets for therapy
US64642505P 2005-01-24 2005-01-24
EP06703354.8A EP1838350B1 (en) 2005-01-20 2006-01-19 Modulators of itch ubiquitinase activity
PCT/GB2006/000181 WO2006077407A2 (en) 2005-01-20 2006-01-19 Modulators of itch ubiquitinase activity

Publications (1)

Publication Number Publication Date
PL1838350T3 true PL1838350T3 (pl) 2015-02-27

Family

ID=36540137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06703354T PL1838350T3 (pl) 2005-01-20 2006-01-19 Modulatory aktywności ubikwitynazy itch

Country Status (5)

Country Link
US (2) US9051572B2 (pl)
EP (1) EP1838350B1 (pl)
CA (1) CA2592172C (pl)
PL (1) PL1838350T3 (pl)
WO (1) WO2006077407A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
MX344555B (es) * 2007-05-08 2016-12-20 Hunter Douglas Ind Switzerland Sistema de color multivariado con aplicacion de textura.
GB201007185D0 (en) * 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination assay
JP2014526887A (ja) * 2011-08-01 2014-10-09 アルナイラム ファーマシューティカルズ, インコーポレイテッド 造血幹細胞移植の成功率を改善する方法
GB201900569D0 (en) 2019-01-15 2019-03-06 Ryboquin Company Ltd Composition, method and use thereof
IT202000023647A1 (it) * 2020-10-07 2022-04-07 Univ Degli Studi Padova Sirna nel trattamento della sindrome ectrodattilia-displasia ectodermica-palatoschisi (eec)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0063456B1 (en) 1981-04-13 1984-08-01 Takeda Chemical Industries, Ltd. Pseudo-aminosugars, their production and use
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1999019357A2 (en) * 1997-10-15 1999-04-22 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US5976849A (en) 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
CA2417368A1 (en) * 2000-08-04 2002-02-14 Xin Lu Suppressor gene
US20030064380A1 (en) 2001-01-29 2003-04-03 The Center For Blood Research, Inc. Anergy-regulated molecules
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
JP2003221349A (ja) 2002-01-25 2003-08-05 Chiba Prefecture p73のアポトーシス誘導調節剤
US20070274915A1 (en) * 2003-10-17 2007-11-29 Anjana Rao Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds
WO2005070044A2 (en) 2004-01-22 2005-08-04 The Cbr Institute For Biomedical Research, Inc. Systems and methods for short rna expression
WO2005079458A2 (en) 2004-02-19 2005-09-01 The Regents Of The University Of California ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE

Also Published As

Publication number Publication date
EP1838350A2 (en) 2007-10-03
WO2006077407A2 (en) 2006-07-27
US9051572B2 (en) 2015-06-09
CA2592172A1 (en) 2006-07-27
WO2006077407A3 (en) 2006-10-19
CA2592172C (en) 2016-06-14
EP1838350B1 (en) 2014-08-20
US9658229B2 (en) 2017-05-23
US20090306187A1 (en) 2009-12-10
US20160084838A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL189975A0 (en) Methods of modulating neurotrophin-mediated activity
PT2120997T (pt) Modulação da atividade de proneurotrofinas
EP1898991A4 (en) MODIFICATION OF PROTEIN ACTIVITY
IL184657A0 (en) Adam-9 modulators
GB0513552D0 (en) Bandage
EP2510925B8 (en) Small-Molecule modulators of TRP-P8 activity
IL189846A0 (en) Theramutein modulators
IL196480A0 (en) Improvement of arginase levels/activity
DK2392335T3 (en) Use of 24-norUDCA
AP1932A (en) Androgen modulators
SI1838350T1 (sl) Modulatorji aktivnosti ubikvitinaze ITCH
GB0501655D0 (en) Therapeutic use
EP1930344A4 (en) POLYPEPTIDE HAVING ANTI-ANGIOGENIC ACTIVITY
GB0424565D0 (en) Activity aid
GB0508439D0 (en) Design of structural elements
GB0510013D0 (en) Interaction of SNEV
GB0521886D0 (en) Glycosyltrasferase activity
TWM292330U (en) Improvement of bed-chair structure
TWM291236U (en) Improved structure of bookrack
PL376281A1 (pl) Aktywny znak drogowy
GB2422130B (en) Inlay activity
ZA200802433B (en) Theramutein modulators
TWM291301U (en) Improvement of mask structure
TWM291302U (en) Improvement of mask structure
TWM292440U (en) Improved structure of sander